Faze Medicines is a pharmaceutical company developing interventions against biomolecular condensates, a newly-discovered driver of disease pathology. Biomolecular condensates, highly dynamic clusters of protein and RNA or DNA, have recently been shown to play an important role in diseases such as amyotrophic lateral sclerosis (ALS), Huntington’s Disease, and cancer. Faze was founded by leaders at the forefront of this exciting new field and aims to revolutionize the treatment of diseases driven by aberrant biomolecular condensates by developing small molecule drugs that address condensate dysregulation. Faze is initially targeting biomolecular condensates implicated in neurodegenerative disorders such as ALS and Myotonic Dystrophy 1 (MD1) given the well-established role of condensates in these indications.
Location: United States, Massachusetts, Cambridge
Total raised: $200M
Investors 2
| Date | Name | Website |
| - | Catalio Ca... | cataliocap... |
| - | SymBiosis | symbiosis.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.12.2020 | Series A | $200M | Third Rock... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 10.12.2020 | With $81M Faze Medicines launch, the condensates field gathe... | The condensates space is where it’s at: With an $81 million financing, Faze Medicines is the third c... | fiercebiot... |
| - | Meet the top young leaders transforming the biotech industry | From left: Dr. Isaac Kinde, head of research and innovation and a co-founder of Thrive, Dr. Asima Ah... | businessin... |
| - | Meet the 30 young leaders forging a new future for the healt... | From left: Dr. Isaac Kinde, Thrive's cofounder and head of research and innovation; Dr. Asima Ahmad,... | businessin... |